Table 7.

Comparison of LSMs of PRO end points over the first six cycles

PRO end points	Sunitinib	Interferon	Difference	P value
FKSI-DRS	28.81	26.38	2.43	<0.0001
FKSI	43.14	39.32	3.82	<0.0001
FACT-G total score	75.71	69.27	6.44	<0.0001
FACT-G physical well-being subscale	20.20	18.82	1.38	0.158
FACT-G social/family well-being subscale	21.71	20.12	1.59	<0.0001
FACT-G emotional well-being subscale	16.73	15.67	1.06	0.019
FACT-G functional well-being subscale	16.81	14.87	1.94	0.019
EQ-5D index (utility score)	0.723	0.674	0.049	0.022
EQ-VAS (health state hermometer score)	68.10	63.45	4.65	0.100

LSMs were estimated using the repeated measures mixed effects model controlling for the time, treatment-by-time interaction and baseline score. A higher score means better outcome (better quality of life or less symptoms).

LSM, least squares mean; PRO, Patient reported outcome; FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Symptom Index–Disease-Related Symptoms; FACT-G, Functional Assessment of Cancer Therapy-General; EQ-5D, EQ-5D self-report questionnaire.